L'oreal

Mark Donovan

Dominique Bernard

Isabelle Castiel

Lucie Simonetti

Aude Foucher

Caroline Delattre

Veronique Chaussade

Sandra Kanani

Virginie Piffaut

Véronique Chaussade

The present invention relates to a method for diagnosing a degradation of esthetic qualities of the skin, based on a measurement of the level of expression of the gene encoding FLG2. The present invention also relates to a method for the cosmetic treatment of skin. The present invention also relates to a method for identifying a compound for reducing and/or slowing the degradation of esthetic quality of the skin, and a kit.

Method of diagnosis of the aesthetic qualities of the skin

The invention also relates to the use of these complex forms for the purposes of screening for biological or chemical compounds capable of modulating a biological activity of said complex forms and/or for preparing and/or improving a pluristratified cell model.

Use of complex forms of calmodulin-like skin protein CLSP

The present invention relates to the use, notably cosmetic and/or therapeutic, of the YKL-40 protein belonging to the family of chitinase-type proteins, of polypeptides derived from this protein or analogs thereof of a nucleic acid sequence encoding such a polypeptide or of an agent that modulates the activity or expression of such a polypeptide notably for stimulation of terminal epithelial differentiation.

Cosmetic use of chitinase-type proteins

The present invention relates to the use of a complex form of calmodulin-like skin protein (CLSP), of polypeptides derived from this protein or of analogues thereof, as a marker for evaluating a state of an epithelium. The invention also relates to the use of these complex forms for the purposes of screening for biological or chemical compounds capable of modulating a biological activity of said complex forms and/or for preparing and/or improving a pluristratified cell model.

The invention relates to the use of one or more complexed or noncomplexed, soluble peptide form(s) of Desmoglein I, as a marker for evaluating the effectiveness of active agents and/or of treatments, in particular anti-ageing active agents and/or treatments, with regard to an epidermis.

Use of soluble forms of the Desmoglein I protein for the purposes of screening for anti-ageing active agents

The present invention relates to the use, in cosmetics and in therapeutics, of at least one antimicrobial protein belonging to the ribonuclease family, ribonuclease 7, or of polypeptides derived from said protein, notably as a marker for evaluating the condition of the epidermis. It further relates to the use of at least one polypeptide according to the invention, of at least one nucleic acid sequence coding for a polypeptide according to the invention, or of at least one agent that modulates the expression or the activity, notably biological, of said polypeptide or of its interaction with an element of the extracellular matrix, for the preparation of compositions intended for the prevention and/or treatment of skin disorders.

Cosmetic use of a protein belonging to the ribonuclease family

The present invention is directed to the use, in particular cosmetic use, of an effective amount of at least one lacritin-type polypeptide, of an analogue thereof or of a fragment thereof, of at least one nucleic acid sequence encoding this polypeptide, or of at least one agent that modulates the activity, the stability or the expression of this polypeptide, or its interaction with syndecan-1, as an agent useful for the care of the skin and of appendages thereof.

Growing community of inventors

Berville, France

Mark Donovan